David Malcom Rodman sold $570k of MLYS
Chief Medical Officer at Mineralys Therapeutics, Inc.. 20,404 shares at an average of $27.93, traded Feb 12, 2026, filed Feb 13, 2026.
Score components
- +15RoleOfficer
- +19Trade size$570k at market
- +10Share of holdings soldSold 36% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -5.1%, 3m -0.8%, 6m -7.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001672659-26-000011, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 12, 2026 | MOption exercise Common Stock10b5-1 | +6,349 | $1.08 | $6,857 | 56,786 | Feb 13, 2026 |
| Feb 12, 2026 | SOpen-market sale Common Stock10b5-1 | -5,828 | $28.94 | $169k | 50,958 | Feb 13, 2026 |
| Feb 12, 2026 | SOpen-market sale Common Stock10b5-1 | -521 | $29.64 | $15k | 50,437 | Feb 13, 2026 |
| Feb 13, 2026 | MOption exercise Common Stock10b5-1 | +3,541 | $10.20 | $36k | 53,978 | Feb 13, 2026 |
| Feb 13, 2026 | SOpen-market sale Common Stock10b5-1 | -3,541 | $27.33 | $97k | 50,437 | Feb 13, 2026 |
| Feb 13, 2026 | MOption exercise Common Stock10b5-1 | +4,166 | $14.25 | $59k | 54,603 | Feb 13, 2026 |
| Feb 13, 2026 | SOpen-market sale Common Stock10b5-1 | -4,166 | $27.33 | $114k | 50,437 | Feb 13, 2026 |
| Feb 13, 2026 | SOpen-market sale Common Stock10b5-1 | -6,348 | $27.58 | $175k | 44,089 | Feb 13, 2026 |
| Feb 12, 2026 | MOption exercise Stock Optionderivative10b5-1 | -6,349 | $0.00 | $0 | 31,743 | Feb 13, 2026 |
| Feb 13, 2026 | MOption exercise Stock Optionderivative10b5-1 | -3,541 | $0.00 | $0 | 127,501 | Feb 13, 2026 |
| Feb 13, 2026 | MOption exercise Stock Optionderivative10b5-1 | -4,166 | $0.00 | $0 | 100,001 | Feb 13, 2026 |
Related signals
Other insiders at Mineralys Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Mineralys Therapeutics, Inc. | Jon Congleton Chief Executive Officer | $1.9M 75,000 shares | -12% | |
| 55Moderate | Mineralys Therapeutics, Inc. | Brian Taylor Slingsby director | $3.0M 104,320 shares | -1% | |
| 12Weak | Mineralys Therapeutics, Inc. | Eric Warren Chief Commercial Officer | $209k 7,438 shares | -16% | |
| 14Weak | Mineralys Therapeutics, Inc. | Daphne Karydas director | $86k 3,000 shares | -33% | |
| 5Weak | Mineralys Therapeutics, Inc. | Eric Warren Chief Commercial Officer | $193k 7,437 shares | -16% | |
| 0Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $59k 2,170 shares | -4% | |
| 12Weak | Mineralys Therapeutics, Inc. | Eric Warren Chief Commercial Officer | $200k 7,438 shares | -16% | |
| 0Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $11k 416 shares | -1% | |
| 34Weak | Mineralys Therapeutics, Inc. | Jon Congleton Chief Executive Officer | $291k 10,700 shares | -2% | |
| 24Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $557k 20,407 shares | -28% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.